文献速递脊柱关节炎

阿巴西普治疗银屑病关节炎的III期随机双盲安慰剂对照研究

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
PubMed 文献 · Ann Rheum Dis · 2017-05-04

这项III期研究将活动性银屑病关节炎患者(约60%曾使用TNF抑制剂)按1:1随机分配至每周皮下注射阿巴西普125 mg(n=213)或安慰剂(n=211)24周。阿巴西普显著提高第24周ACR20应答率(39.4% vs 22.3%;p<0.001),但健康评估问卷残疾指数应答率差异未达统计学显著(31.0% vs 23.7%;p=0.097),对银屑病皮损改善有限,耐受性良好。

要点

  • 阿巴西普显著提高第24周ACR20应答率(39.4% vs 22.3%;p<0.001)。
  • HAQ-DI应答率数值上提高但未达统计学显著(31.0% vs 23.7%;p=0.097)。
  • 对银屑病皮损改善有限,耐受性良好,无新安全信号。

核心结论

  • 阿巴西普治疗银屑病关节炎达到主要终点ACR20应答,在肌肉骨骼表现方面总体显示有益趋势且耐受性良好。
  • 阿巴西普对银屑病皮损的影响有限。

研究设计与样本

  • III期随机双盲安慰剂对照研究,活动性银屑病关节炎患者按1:1随机分配至每周皮下阿巴西普125 mg(n=213)或安慰剂(n=211)24周,随后开放标签阿巴西普。
  • 第16周关节计数改善未达≥20%的患者转为开放标签阿巴西普。

主要发现

  • 第24周阿巴西普组ACR20应答率39.4%,安慰剂组22.3%(p<0.001)。
  • 第24周HAQ-DI应答率(较基线下降≥0.35)阿巴西普组31.0%,安慰剂组23.7%(p=0.097)。
  • 无论是否曾暴露于TNF抑制剂,ACR20应答均可见阿巴西普获益。
  • 疗效维持或改善至第52周。

关键数值与推荐

  • 主要终点为第24周达到ACR20标准的患者比例。
  • HAQ-DI应答定义为较基线下降≥0.35。

临床怎么用

  • 阿巴西普可作为活动性银屑病关节炎的一种治疗选择,包括曾使用TNF抑制剂的患者。
  • 对银屑病皮损的改善有限,需关注皮肤病变的患者应权衡获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the efficacy and safety of abatacept, a selective T-cell costimulation modulator, in a phase III study in psoriatic arthritis (PsA). METHODS: This study randomised patients (1:1) with active PsA (~60% with prior exposure to a tumour necrosis factor inhibitor) to blinded weekly subcutaneous abatacept 125 mg (n=213) or placebo (n=211) for 24 weeks, followed by open-label subcutaneous abatacept. Patients without ≥20% improvement in joint counts at week 16 were switched to open-label abatacept. The primary end point was the proportion of patients with ≥20% improvement in the American College of Rheumatology (ACR20) criteria at week 24. RESULTS: Abatacept significantly increased ACR20 response versus placebo at week 24 (39.4% vs 22.3%; p<0.001). Although abatacept numerically increased Health Assessment Questionnaire-Disability Index response rates (reduction from baseline ≥0.35) at week 24, this was not statistically significant (31.0% vs 23.7%; p=0.097). The benefits of abatacept were seen in ACR20 responses regardless of tumour necrosis factor inhibitor exposure and in other musculoskeletal manifestations, but significance could not be attributed due to ranking below Health Assessment Questionnaire-Disability Index response in hierarchical testing. However, the benefit on psoriasis lesions was modest. Efficacy was maintained or improved up to week 52. Abatacept was well tolerated with no new safety signals. CONCLUSIONS: Abatacept treatment of PsA in this phase III study achieved its primary end point, ACR20 response, showed beneficial trends overall in musculoskeletal manifestations and was well tolerated. There was only a modest impact on psoriasis lesions. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov number, NCT01860976 (funded by Bristol-Myers Squibb).

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017. PMID: 28473423. doi:10.1136/annrheumdis-2016-210724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。